Loading
A phase 1/2 trial of Dual-target CAR-NK cell product in ovarian cancer, run by Beijing Biotech, now recruiting.
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) is a phase 1/2 interventional study registered as NCT07480954 by Beijing Biotech, with 36 participants planned, started 2026-02-04 and due to reach its primary completion in 2027-02-17. Interventions recorded: Dual-target CAR-NK cell product and Lymphodepleting chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Folate receptor alpha, Ovarian cancer and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares Mesothelin and the tag pipeline.
Shares High-grade serous ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Folate receptor alpha, Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/